Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera

Journal of Clinical Oncology

Volumn 26, Issue 31, 2008, Pages 5060-5066

  Qiu, Ji ^a   Choi, Gina ^a   Li, Lin ^a   Wang, Hong ^a   Pitteri, Sharon J ^a   Pereira Faca, Sandra R ^a   Krasnoselsky, Alexei L ^a   Randolph, Timothy W ^a   Omenn, Gilbert S ^a   Edelstein, Cim ^a   Barnett, Matt J ^a   Thornquist, Mark D ^a   Goodman, Gary E ^a   Brenner, Dean E ^a   Feng, Ziding ^a   Hanash, Samir M ^a  

^a Fred Hutchinson Cancer Research Center

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; LAMR 1 ANTIGEN; LIPOCORTIN 1; PGP9.5 ANTIGEN; PYROXYLIN; THY 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PATIENT; CELL FRACTIONATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; VALIDATION STUDY;

14-3-3 PROTEINS; ADENOCARCINOMA; ANNEXIN A1; AUTOANTIBODIES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; EARLY DIAGNOSIS; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; RECEPTORS, LAMININ; REPRODUCIBILITY OF RESULTS; UBIQUITIN THIOLESTERASE;

EID: 55549117480     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.2388     Document Type: Article

References (68)

1. Stockert E, Jager E, Chen YT, et al: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349-1354, 1998
2. Tan EM: Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 108:1411-1415, 2001
3. Mintz PJ, Kim J, Do KA, et al: Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21:57-63, 2003
4. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, et al: Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934-938, 1995
5. Güre AO, Altorki NK, Stockert E, et al: Human lung cancer antigens recognized by autologous antibodies: Definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res 58:1034-1041, 1998
6. Yamamoto A, Shimizu E, Ogura T, et al: Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer 69:283-289, 1996
7. Dunn GP, Bruce AT, Ikeda H, et al: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3:991-998, 2002
8. Hanash S: Harnessing immunity for cancer marker discovery. Nat Biotechnol 21:37-38, 2003
9. Old LJ, Chen YT: New paths in human cancer serology. J Exp Med 187:1163-1167, 1998
10. Finn OJ: Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 353:1288-1290, 2005
11. Diesinger I, Bauer C, Brass N, et al: Toward a more complete recognition of immunoreactive antigens in squamous cell lung carcinoma. Int J Cancer 102:372-378, 2002
12. Güre AO, Stockert E, Scanlan MJ, et al: Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 97:4198-4203, 2000
13. Ali Eldib AM, Ono T, Shimono M, et al: Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma. Int J Cancer 108:558-563, 2004
14. Yang F, Xiao ZQ, Zhang XZ, et al: Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 6:751-758, 2007
15. Hanash S: Disease proteomics. Nature 422:226-232, 2003
16. Imafuku Y, Omenn GS, Hanash S: Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers 20:149-153, 2004
17. Brichory F, Beer D, Le Naour F, et al: Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 61:7908-7912, 2001
18. Brichory FM, Misek DE, Yim AM, et al: An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 98:9824-9829, 2001
19. Pereira-Faca SR, Kuick R, Puravs E, et al: Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res 67:12000-12006, 2007
20. Wang H, Hanash S: Multi-dimensional liquid phase based separations in proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 787:11-18, 2003
21. Faca V, Pitteri SJ, Newcomb L, et al: Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 6:3558-3565, 2007
22. Nam MJ, Madoz-Gúrpide J, Wang H, et al: Molecular profiling of the immune response in colon cancer using protein microarrays: Occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 3:2108-2115, 2003
23. Madoz-Gúrpide J, Kuick R, Wang H, et al: Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 7:268-281, 2008
24. Forrester S, Qiu J, Mangold L, et al: An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays. Proteomics Clin Appl 1:494-505, 2007
25. Goodman GE, Thornquist MD, Balmes J, et al: The Beta-Carotene and Retinol Efficacy Trial: Incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 96:1743-1750, 2004
26. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996
27. Qiu J, Madoz-Gurpide J, Misek DE, et al: Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 3:261-267, 2004
28. Friedman J, Hastie T, Tibshirani R: Additive logistic regression: A statistical view of boosting. Ann Stat 28:337-407, 2000
29. Yasui Y, Pepe M, Thompson ML, et al: A data-analytic strategy for protein biomarker discovery: Profiling of high-dimensional proteomic data for cancer detection. Biostatistics 4:449-463, 2003
30. Madoz-Gúrpide J, Wang H, Misek DE, et al: Protein based microarrays: A tool for probing the proteome of cancer cells and tissues. Proteomics 1:1279-1287, 2001
31. He P, Naka T, Serada S, et al: Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 98:1234-1240, 2007
32. Türeci O, Mack U, Luxemburger U, et al: Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 236:64-71, 2006
33. Chang JW, Lee SH, Jeong JY, et al: Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 579:2873-2877, 2005
34. Yagihashi A, Asanuma K, Kobayashi D, et al: Detection of autoantibodies to livin and survivin in sera from lung cancer patients. Lung Cancer 48:217-221, 2005
35. Matsumoto S, Teramoto H, Nakamoto M, et al: Presence of antibodies against retinoblastoma tumor suppressor protein in patients with lung cancer. Int J Oncol 19:1035-1039, 2001
36. Fernández-Madrid F, VandeVord PJ, Yang X, et al: Antinuclear antibodies as potential markers of lung cancer. Clin Cancer Res 5:1393-1400, 1999
37. Lubin R, Zalcman G, Bouchet L, et al: Serum p53 antibodies as early markers of lung cancer. Nat Med 1:701-702, 1995
38. Yow HK, Wong JM, Chen HS, et al: Increased mRNA expression of a laminin-binding protein in human colon carcinoma: Complete sequence of a full-length cDNA encoding the protein. Proc Natl Acad Sci U S A 85:6394-6398, 1988
39. Butò S, Tagliabue E, Ardini E, et al: Formation of the 67-kDa laminin receptor by acylation of the precursor. J Cell Biochem 69:244-251, 1998
40. Rao CN, Castronovo V, Schmitt MC, et al: Evidence for a precursor of the high-affinity metastasis-associated murine laminin receptor. Biochemistry 28:7476-7486, 1989
41. Lesot H, Kuhl U, Mark KV: Isolation of a laminin-binding protein from muscle cell membranes. Embo J 2:861-865, 1983
42. Malinoff HL, Wicha MS: Isolation of a cell surface receptor protein for laminin from murine fibrosarcoma cells. J Cell Biol 96:1475-1479, 1983
43. Auth D, Brawerman G: A 33-kDa polypeptide with homology to the laminin receptor: Component of translation machinery. Proc Natl Acad Sci U S A 89:4368-4372, 1992
44. Ardini E, Pesole G, Tagliabue E, et al: The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol 15:1017-1025, 1998
45. Coggin JH Jr, Barsoum AL, Rohrer JW: 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res 19:5535-5542, 1999
46. Coggin JH Jr, Barsoum AL, Rohrer JW: Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. Immunol Today 19:405-408, 1998
47. Rieger R, Edenhofer F, Lasmezas CI, et al: The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 3:1383-1388, 1997
48. Wewer UM, Taraboletti G, Sobel ME, et al: Role of laminin receptor in tumor cell migration. Cancer Res 47:5691-5698, 1987
49. Ménard S, Tagliabue E, Colnaghi MI: The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 52:137-145, 1998
50. Ménard S, Castronovo V, Tagliabue E, et al: New insights into the metastasis-associated 67 kD laminin receptor. J Cell Biochem 67:155-165, 1997
51. Cioce V, Castronovo V, Shmookler BM, et al: Increased expression of the laminin receptor in human colon cancer. J Natl Cancer Inst 83:29-36, 1991
52. Fontanini G, Vignati S, Chine S, et al: 67-Kilodalton laminin receptor expression correlates with worse prognostic indicators in non-small cell lung carcinomas. Clin Cancer Res 3:227-231, 1997
53. Ambrose KR, Anderson NG, Coggin JH: Interruption of SV40 oncogenesis with human foetal antigen. Nature 233:194-195, 1971
54. Coggin JH Jr, Ambrose KR, Bellomy BB, et al: Tumor immunity in hamsters immunized with fetal tissues. J Immunol 107:526-533, 1971
55. Ambrose KR, Anderson NG, Coggin JH Jr: Cytostatic antibody and SV40 tumour immunity in hamsters. Nature 233:321-324, 1971
56. Payne WJ Jr, Coggin JH Jr: Mouse monoclonal antibody to embryonic antigen: Development, cross-reactivity with rodent and human tumors, and preliminary polypeptide characterization. J Natl Cancer Inst 75:527-544, 1985
57. Coggin JH Jr, Rohrer SD, Leinbach ED, et al: Radiation-induced lymphoblastic lymphomas/leukemias and sarcomas of mice express conserved, immunogenic 44-kilodalton oncofetal antigen. Am J Pathol 130:136-146, 1988
58. Gussack GS, Rohrer SD, Hester RB, et al: Human squamous cell carcinoma lines express oncofetal 44-kD polypeptide defined by monoclonal antibody to mouse fetus. Cancer 62:283-290, 1988
59. Rohrer JW, Rohrer SD, Barsoum A, et al: Differential recognition of murine tumor-associated oncofetal transplantation antigen and individually specific tumor transplantation antigens by syngeneic cloned BALB/c and RFM mouse T cells. J Immunol 152:754-764, 1994
60. Siegel S, Wagner A, Friedrichs B, et al: Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol 176:6935-6944, 2006
61. Rohrer JW, Culpepper C, Barsoum AL, et al: Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning. J Immunol 154:2266-2280, 1995
62. Höltl L, Zelle-Rieser C, Gander H, et al: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369-3376, 2002
63. Rohrer JW, Coggin JH Jr: CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 155:5719-5727, 1995
64. Rohrer JW, Barsoum AL, Coggin JH Jr: Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones. J Immunol 176:2844-2856, 2006
65. Rohrer JW, Barsoum AL, Dyess DL, et al: Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J Immunol 162:6880-6892, 1999
66. Rohrer J, Barsoum A, Coggin JH Jr: The development of a new universal tumor rejection antigen expressed on human and rodent cancers for vaccination, prevention of cancer, and anti-tumor therapy. Mod Asp Immunobiol 1:191-195, 2001
67. Coggin JH Jr, Rohrer SD, Hester RD, et al: 44-kd oncofetal transplantation antigen in rodent and human fetal cells: Implications of recrudescence in human and rodent cancers. Arch Otolaryngol Head Neck Surg 119:1257-1266, 1993
68. Rohrer SD, Sarli RN, Barsoum AL, et al: Expression of 44-kilodalton oncofetal antigen as a premalignancy marker in X irradiation-induced murine T-cell lymphoma. J Natl Cancer Inst 84:602-609, 1992